Study Comparing Whole Breast Radiotherapy With a Daily Versus a Weekly Tumor
Completed · Phase 3
Conditions studied: Breast Cancer
In brief
All patients (with Stages 0-II breast cancer) will receive an accelerated three week regimen of prone whole breast radiotherapy. The study intends to test the hypothesis that a weekly boost to the tumor bed, delivered on Friday, before the weekend break, is as well tolerated as the daily boost during accelerated prone radiotherapy.
Key facts
- Study ID
- NCT01000662
- Run by
- NYU Langone Health
- People needed
- 412
- Starts
- 2009-03-01
- Expected to finish
- 2017-06-14
- Last updated by the study team
- 2020-08-06
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Pre or post-menopausal women with stage 0,I, and II breast cancer
- Biopsy-proven invasive breast cancer, excised with negative margins of at least 1 mm
- Status post segmental mastectomy, after sentinel node biopsy and/or axillary node dissection (DCIS and Tumors <5mm do not require nodal assessment)
- At least 2 weeks from last chemotherapy
- Patient needs to be able to understand and demonstrate willingness to sign a written informed consent document
You may not qualify if…
- Previous radiation therapy to the ipsilateral breast
- More than 3 involved nodes identified at axillary staging, requiring adjuvant axillary radiation
- Active connective tissue disorders, such as lupus or scleroderma
- Prior or concurrent malignancy other than basal or squamous cell skin cancer or carcinoma in-situ of the cervix, unless disease-free >3 years
- Pregnant or lactating women
Where it is running
- Bellevue Hospital Center — New York, New York, United States
- NYU Clinical Cancer Center — New York, New York, United States
- Tisch Hospital — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.